论文信息 - 532 Evaluation of a BRCAness signature as a predictive biomarker of response to veliparib/carboplatin plus standard neoadjuvant therapy in high-risk breast cancer: results from the I-SPY 2 trial - 字舞流文

532 Evaluation of a BRCAness signature as a predictive biomarker of response to veliparib/carboplatin plus standard neoadjuvant therapy in high-risk breast cancer: results from the I-SPY 2 trial

D. Berry | A. Glas | N. Hylton | O. Olopade | T. Severson | D. Yee | C. Yau | S. Linn | A. Sanil | F. Symmans | J. Peeters | M. Paoloni | M. Buxton | H. Rugo | L. Esserman | D. Wolf | A. Demichele | Yunlei Li | L. Veer